Amuthakannan Subramaniam

Amuthakannan Subramaniam has extensive experience in the field of pharmaceutical research and development. Amuthakannan has held various roles in different companies throughout their career.

From 2021 to the present, Subramaniam has been working as a Principal Scientist at Intercept Pharmaceuticals.

Prior to that, from 2019 to 2021, they worked as a Senior Research Scientist at Bausch Health Companies Inc., where they served as the pharmacology and toxicology lead on various projects. Their responsibilities included authoring nonclinical sections for IND and NDAs, managing studies, and coordinating activities with CROs.

From 2018 to 2019, Subramaniam worked as a Senior Researcher at Bionaut Labs, leading pharmacology and toxicology efforts in oncology projects.

Subramaniam also served as a Scientist at Trefoil Therapeutics from 2015 to 2018, where they conducted preclinical studies in ocular disease drug discovery projects.

From 2011 to 2014, they worked as a Project Manager and Independent Contractor at GS Consulting, where they coordinated drug discovery and non-clinical drug development programs for various clients.

In 2010, Subramaniam held the position of Project Manager and Therapeutic Area Expert at HUYA Bioscience International, where they evaluated preclinical and clinical data and identified in-licensing opportunities.

From 2007 to 2010, they worked as a Research Scientist II at Exelixis, leading the TGR5 program and contributing to the nomination of a TGR5 agonist.

Subramaniam's earlier experiences include roles as a Senior Scientist at Ionis Pharmaceuticals, Inc. from 2003 to 2007, where they designed and conducted efficacy assays for cardiovascular targets, and as a Postdoctoral Scientist at the University of Pennsylvania in 2003.

Amuthakannan began their career as a Scientist at Calyx Therapeutics, Inc. in 2002, where they were involved in the discovery and procurement of plant materials for diabetes and inflammation programs.

Overall, Subramaniam's work experience showcases their expertise in pharmacology and toxicology, preclinical studies, project management, and scientific evaluation in the pharmaceutical industry.

Amuthakannan Subramaniam pursued their education in a chronological order. From 1989 to 1995, they attended the Tamil Nadu Dr. M.G.R. Medical University in Chennai, where they obtained a degree in B.S.M.S in Siddha Medicine. Amuthakannan furthered their studies from 1996 to 2001 at the University of Buckingham, where they earned a D.Phil degree in Life Sciences.